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Bovine-viral-diarrhea virus (BVDV) can cause significant economic losses in livestock.
The disease is controlled with vaccination and bovines are susceptible until vaccine
immunity develops and may remain vulnerable if a persistently infected animal is left on
the farm; therefore, an antiviral agent that reduces virus infectivity can be a useful tool
in control programs. Although many compounds with promising in-vitro efficacy have
been identified, the lack of laboratory-animal models limited their potential for further
clinical development. Recently, we described the activity of type I and III interferons,
IFN-α and IFN-λ respectively, against several BVDV strains in-vitro. In this study, we
analyzed the in-vivo efficacy of both IFNs using a BALB/c-mouse model. Mice infected
with two type-2 BVDV field strains developed a viremia with different kinetics, depending
on the infecting strain’s virulence, that persisted for 56 days post-infection (dpi). Mice
infected with the low-virulence strain elicited high systemic TNF-α levels at 2 dpi. IFNs
were first applied subcutaneously 1 day before or after infection. The two IFNs reduced
viremia with different kinetics, depending on whether either one was applied before or
after infection. In a second experiment, we increased the number of applications of both
IFNs. All the treatments reduced viremia compared to untreated mice. The application
of IFN-λ pre- and post-infection reduced viremia over time. This study is the first proof
of the concept of the antiviral potency of IFN-λ against BVDV in-vivo, thus encouraging
further trails for a potential use of this cytokine in cattle.
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INTRODUCTION
Bovine-viral-diarrhea virus (BVDV) is a single-stranded RNA virus that belongs to the
family Flaviviridae, genus Pestivirus—along with border-disease virus and classical swine-fever
virus—known to infect a wide range of wild and domesticated ruminants and porcine species (1, 2).
BVDV is divided into two principal species, both including viruses of two biotypes, cytopathic,
and noncytopathic (ncp), according to their activity in cultured cells. Acute ncp-BVDV infection
is associated with diarrhea, respiratory disease, hemorrhagic syndrome, abortion, the weak-calf
syndrome, teratogenic effects on fetuses, and mucosal disease (3, 4). The virus also causes severe
immunosuppression that predisposes the infected animal to opportunistic pathogens. Moreover,
persistence can be developed by in-utero infection with a ncp strain. Persistently infected (PI)
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animals are immunotolerant to the infecting strain and
continuously disperse the virus within the herd.
BVDV is transmitted with high efficiency within infected
herds, resulting in outbreaks and clinical disease that negatively
affect production parameters. Vaccination applied to persistent-
infection-free herds constitutes the only efficient tool for
controlling BVDV. Nevertheless, even if vaccination is correctly
applied and high-quality vaccines are used, development of
adaptive immunity leaves a vulnerability window whose extent
has not yet been defined. Vaccine failure is also favored by the
presence of PI animals, the lower efficacy of vaccines in animals
with maternal immunity, and the emergence of new viral strains
not included in the vaccine, among other issues. In this scenario,
the use of an effective antiviral agent is paramount.
The type-I and type-III interferons (IFNs) are virus-induced
cytokines that potently restrict viral replication during the first
days of infection before activation of the adaptive immune system
occurs (5, 6). The type-I IFN family consists of several IFN-α
subtypes, a single IFN-β and several minor members that all bind
to and act via the IFN-α/ß–receptor complex, expressed on most
nucleated cells (5, 6) with the possible exception of intestinal
epithelium (7, 8). The members of the type-III IFN family (IFN-
λ1, IFN-λ2, and IFN-λ3) bind to a different receptor complex
(the IFN-λ receptor), which is highly expressed on epithelial
cells (5, 9). Although type-I and -III IFNs use different receptor
complexes, both cytokines activate similar signal pathways (9, 10)
and possess comparable antiviral activities (11), though toxicity is
usually lower for IFN-λ because of its cell-type–restricted target.
These IFNs have been tested in-vivo (12–18), revealing high non-
specific antiviral activities; and although action of these cytokines
is exerted in different cell types, no reports have appeared in the
literature on experiments that evaluate the combined use of IFN-I
and -III for the prophylaxis and/or therapeutic treatment of viral
infections in-vivo.
BVDV is used as a model virus for human hepatitis C
antiviral studies (19, 20); therefore, many antiviral agents have
been developed (21). Human as well as bovine IFNs have been
tested against BVDV in-vitro (22), but the in-vivo efficacy has
been difficult to demonstrate. Most of the efforts in using IFNs
as antiviral cytokines for cattle have focused on treating PI
animals (23)—and with arguable success—but controlling acute
infections in-vivo has not been assessed thus far. Moreover,
circulating BVDV strains are ncp, which complicates measuring
infectivity in vitro.
Viral mechanisms that counteract IFN-α activity have been
identified, but, acute BVDV infection with ncp strains induces
high levels of systemic IFN-α and other IFNs in the infected cattle
(24), meaning that these IFNs may be functional within an in-
vivo situation. To the best of our knowledge, no evidence has
been garnered for the use of IFN-α or other IFNs to prevent
and/or treat acute BVDV infection in-vivo. We have recently
demonstrated that several BVDV strains are susceptible to bovine
IFN-α and IFN-λ in vitro. We also developed a method to easily
measure infectivity of BVDV by visualizing infected cells using
a monoclonal antibody against a non-structural protein (NS3),
considered a marker of virus replication (25). Recently, a mouse
model of BVDV infection was set-up and tested with several
strains showing that mice developed viremia without clinically
manifest disease (26, 27). In this study, we made use of all these
tools, set up the BALB/c infection model for 2-well characterized
type-2 ncp BVDV strains (28) and evaluated the efficacy of




The Madin-Darby bovine-kidney (MDBK) cell line from the
American Type Culture Collection (ATCC) was provided by
the Institute of Virology (INTA) Argentina. The cells were
cultured in Dulbecco’s Modified Eagle’s Minimal Essential
Medium (DMEM, Gibco) with 10% (v/v) gamma globulin-free,
mycoplasma-tested and virus-screened fetal bovine serum (FBS,
HI FBS Qualified, Gibco). FBS was also controlled for the BVDV
genome by RT-PCR following a standard protocol (see below).
The absence of live virus in the FBS was further corroborated
by serial passage in MDBK cells followed by immunofluorescent
staining as previously described (29).
Two genotype-2 ncp BVDV strains were used: the reference
BVDV NY-93 high-virulent strain (GenBank accession number
AF502399) and the low-virulent field strain isolated in the
Buenos Aires province, Argentina (BVDV 98-124, GenBank
accession number MH074881). Both strains had been previously
characterized in a colostrum-deprived-calf model (28). BVDV
stocks were produced by infecting MDBK cells, following
standard procedures (30). Titers were 8.26 × 106 and 5.24 × 106
50% tissue-culture–infective-dose (TCID50)/ml for the 98-124
and NY-93 strains, respectively.
Animals
Female BALB/c mice, 6–8 weeks’ old weighing 18–20 g were
purchased from the animal facility of the School of Veterinary
Science, University of Buenos Aires. All the feeding and
experimental procedures were carried out under specific
pathogen-free conditions at the animal experimental center of
our institute (INTA). The animals were housed in a temperature-
and light-controlled environment and had free access to food and
sterile water ad libitum. After acclimatization to the light-dark
cycle for 1 week, the experiment was started. The procedures
with the mice were performed following national animal-welfare
regulations (Protocol N◦ 6/2017 CICUAE, INTA).
Antibodies
Fluorescein isothiocyanate- (FITC-) conjugated polyclonal
commercial antibody against BVDV (VMRD BVDV Direct FA
Conjugate, WA, USA) was used to visualize the presence of virus
by immunofluorescence. The monoclonal antibody anti-NS3
was kindly provided by Dr. Gerrit Keizer (Prionics).
Mouse-BVDV–Infection Model
Two groups of eight mice each were inoculated intraperitoneally
(IP) with 0.4mL of DMEM (Gibco) without serum, containing
1.25 × 106 TCID50/ml of the BVDV NY-93 or 98-124 strains.
Mock-infectedmice (n= 4) were administered 0.4mL of DMEM.
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The virus stocks were produced according to the procedures
described above but with culture media without FBS. The
animals’ weights and body temperatures were controlled during
the experiment. Whole-blood and serum samples were taken
at the beginning of the experiment and at 2, 4, and 7 days
post-infection (dpi) and viremia assessed by In-Cell ELISATM.
Proinflammatory cytokines were measured at 0, 2, and 4 dpi with
a commercial kit (the BD R© CBA inflammation kit). The mice
were euthanized at 7 dpi and the heart, spleen, liver, kidney,
mesenteric lymph nodes, and brains removed. Each organ was
divided into two equal parts that were used for histopathological
analysis and for virus isolation as described previously (28).
In a second experiment, two groups of five mice each were
infected with the 98–124 strain, or mock-infected, and sampled
at 0, 4, 7, 10, 14, 21, 35, 43, and 56 dpi. The sera were aliquoted
and stored at −80◦C until use. The mice were euthanized at the
end of the experiment and the spleen, liver, andmesenteric lymph
nodes removed and processed for histopathology and RT-nested
PCR, as detailed below.
Prophylaxis and Treatment With
IFNs-Experimental Design
Experiment 1: Thirty-seven BALB/c mice were randomly divided
into eight groups. Each group received recombinant mouse
IFN-α (250,000 U/dose, Miltenyi Biotec R©, Alemania) or IFN-
λ (2 µg/dose, Sigma R©) by subcutaneous injection. The latter
were selected on the basis of previous reports (31–34). BVDV
98–124 was inoculated IP, as described above. The IFNs were
administered the day before infection (−1 dpi: i.e., the “pre-
infection” groups, n = 5 each) or the day after infection (+1 dpi,
“post-infection” groups, n= 5 each). Mock-treatedmice received
PBS (the buffer used to dilute the IFNs) on −1 and also +1 dpi
(n = 5). The mock-infected mice received DMEM at 0 dpi (n =
6), these animals were not treated with IFNs. Another two groups
of three animals each that were inoculated with each IFN but not
infected were used as the treatment controls.
Experiment 2: Forty BALB/c mice were randomly divided
into eight groups of five animals each. IFNs were administered
at the same doses as in Experiment 1. Each group received the
IFNs before (−2 and −1 dpi) or after (+1 and +2 dpi) the
infection. The mock-treated group received PBS both before and
after infection. Infection was carried out at 0 dpi with the mock-
infected mice receiving DMEM at the same time point (the naïve
group). The serum samples were collected at 0, 2, 4, 7, 10, 15, 20,
and 30 dpi and stored at−20◦C until use.
Viremia
Viremia was determined in individual- or pooled- serum samples
added to MDBK cells monolayers by revealing virus infectivity
with a monoclonal antibody against NS3 (25). The protocol of
this so-called “In-Cell ELISA,” has been described previously
and was applied with the following modifications. To MDBK
cells grown in 96-well culture plates (1.5 × 103 cells/well), 50
µl of serial 2-fold dilutions (1/4–1/320) of serum were added
to duplicate wells before incubation at 37◦C, for 1 h in an
atmosphere of 5% CO2. The inoculum was then removed by
washing the cells with PBS 1x and the plates incubated for
48 h at 37◦C−5% CO2. The monolayers were fixed with 4%
(v/v) formaldehyde in PBS for 20min, permeabilized with 0.01%
(v/v) Triton X-100 in PBS for 20min at room temperature, and
finally blocked with 10% (v/v) equine serum in PBS for 90min.
The resulting supernatants were then gently aspirated and the
primary antibody (mAb anti-NS3, Prionics) was added followed
by incubation for 1 h at 37◦C. The reaction was revealed with an
anti-mouse peroxidase conjugate and the substrate 2,2′-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) [ABTS]. To account for
differences in cell seeding, the density was normalized according
to the readings at 595 nm after staining with the dye Janus-Green
(SIGMA, San Luis, MO; at 50 µl/well). Once normalized, the
ABTS-OD450 values of each sample were subtracted from those
of the mock-treated wells to give the corrected OD450 values,
which were then averaged. For NS3 titration, the inverse of the
last dilution giving a value over the cut-off of the assay (OD =
0.2) was informed.
Cytokine Measurement
IFN-γ, MCP-1, IL-6, IL-10, and TNF-α, were quantified in serum
samples using the commercial CBA inflammation kit (BD R©)
according to the manufacturer’s instructions. Briefly: Samples
were diluted 1:2 in assay diluent then mixed with 60 µl of the
Capture Beads Mix from the kit. Fifty microliters of Mouse
Inflammation PE Detection Reagent was added and incubated
for 2 h in the dark, at room temperature. The cells were next
washed twice, centrifuged at 200 g for 5min, and finally analyzed
by flow cytometry.
Alternatively, commercial TNF-α- and IL-10–precoated
sandwich-ELISA kits were used (BD Pharmingen, San Diego,
CA) according to the manufacturer’s instructions. Briefly, 100 µl
of capture Antibody were added per well and incubated overnight
at 4◦C. After three washes, the plates were blocked with 10%
(v/v) FBS in PBS and incubated for 1 h at room temperature.
The samples were diluted 1:2 in 10% (v/v) FBS in PBS and 100
µl added to each well followed by an incubation for 2 h at room
temperature. After washing, the plates were incubated with the
corresponding detection solution of antibody plus streptavidin-
bound horseradish peroxidase, and TMB (BioSite TM 4125). The
reaction was stopped with 2N H2SO4 and plates read at 450 nm.
RT Nested PCR
RNA was extracted from whole blood and minced organs using
a commercial kit (High Pure RNA Tissue Kit, Roche) following
the manufacturer’s instructions. RNA samples were quantified in
a NanoDrop R© (Thermo Fisher Scientific, Wilmington, DE). The
values for the ratio of absorbance at 260/280 nm and 260/230 nm
were considered an assessment of the purity of the extracted
RNA. The reverse transcription was carried out with Moloney-
murine-leukemia-virus reverse transcriptase and the rev-326
primer (35). The nested PCR was conducted in a conventional
thermocycler (T-18, Ivema SRL, Argentina) following a protocol
developed by Jones et al. (36). The first round involved the
use of the Pan-Pestivirus 324 and 326 primers (35) at 300 nM,
the second round the Pesti-3 and Pesti-4 primers (37) at the
same concentration. The reaction products were analyzed by
electrophoresis in a 1.5% (w/v) agarose gel and compared with a
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ladder of molecular-weight markers (Cien Marker, Biodynamics
SRL). A band of 171 bp is expected for positive detection.
Histopathology
The ablated organs (liver, spleen, heart, kidney, mesenteric lymph
nodes, and brain) were immediately fixed in 10% (v/v) neutral
buffered formaldehyde and embedded in paraffin. The fixed
organs were sliced and stained with hematoxylin and eosin
followed by histopathological analysis by microscopy.
Data Analysis
Paired-comparisons were performed with the Mann-Whitney
test. The results between different experimental groups with
respect to the areas under the absorbance curves in Figures 3C,D
and Figure 5B were compared by means of the Krustall-Wallis
test, followed by the Dunn’s multiple-comparisons test. In all
instances, a confidence interval of 95% was considered. The
analysis was performed with GraphPad Prism v5.0 (GraphPad
Software, CA, USA).
RESULTS
Setup of the BVDV-Mouse Model: Infection
With Low- and High-Virulence Type-II
Strains
In the present study, BALB/c mice were infected with 2-
well characterized ncp BVDV–genotype-2 strains of different
virulence (28), following recently published protocols (26, 27).
In the first experiment, groups of eight BALB/c mice were
inoculated IP with either BVDV strain or PBS. None of the
mice exhibited any clinical signs of illness—neither changes
in feeding patterns nor alterations in behavior associated with
malaise. BVDV infection, furthermore, did not affect the mice’s
weight gain (Figure 1A) or modify their body temperature (data
not shown) during the whole experiment. Viremia was assessed
in serum samples by seeding each serum sample on MDBK
cells and revealing virus replication with the NS3-In-Cell ELISA
(Figure 1B). Viremia was first detected at 4 dpi for the high-
virulence strain NY-93 and at 7 dpi for the field isolate 98-124.
The IFN-γ levels increased significantly at 2 dpi (p < 0.05) in
mice infected with strain 98-124 while in mice infected with NY-
93 the increase that occurred was not significant (p = 0.052;
Figure 1C). The low-virulence strain 98-124, induced an increase
in the systemic levels of TNF-α at 2 dpi that decreased by 4
dpi (Figure 1D); and since the cytokine evidenced no change
in the NY-93–bearing mice, the TNF-α levels were comparable
in all three groups at that later time. The rest of the cytokines
as well as the chemokine MCP-1 did not manifest significant
differences between the groups (data not shown). Viral RNA was
detected by RT-PCR in blood samples at 7 dpi in all infected
animals. The results from the histopathological analysis did not
detect any lesions that could be associated with the infection (data
not shown).
The infected mice did not resolve the viremia by a week’s
time post-infection; in fact, at that time high levels were
achieved (Figure 1B). In order to complete the viremia curve, we
monitored the infected animals for another 56 days. During this
time the infected mice failed to evidence any clinical signs of the
disease or underwent any change in weight or behavior compared
to the naïve animals, although the virus remained in circulation
for up to 56 dpi within levels similar to those measured at 7 dpi
(Figure 2).
Use of IFN-α and -λ for the Prophylaxis or
Treatment of BVDV Infection
The activity of both IFNs was then assessed using BVDV 98-124
in the mouse model. This virus strain was selected because it is a
regional representative of typical type 2 strain (28) and also due to
the 2 dpi TNF-α systemic innate response induced by this strain
that can be easily measured in sera.
Type-I and -III IFNs were applied either before or after
infection (Figure 3). A peak of viremia was observed at 7 dpi
in the infected, untreated mice (PBS group) as seen above
(Figure 1B), whose levels thereafter were maintained for up to
30 dpi. Mock-infected animals, either treated or not with IFNs,
did not develop viremia and no signs of discomfort or changes
in behavior, temperature and weight gain were observed due
to the IFN-treatment (data not shown). IFN-λ applied before
infection (Figure 3A) reduced the viremia to values significantly
lower than those observed in the PBS group at 7, 10, and
30 dpi (p = 0.0307, 0.0317, and 0.0378, respectively; cf. the
asterisks in Figure 3A); whereas the application of IFN-λ post-
infection had no effect in reducing virus levels with respect to
that untreated group.
The treatment with IFN-α post-infection diminished the
mean viremia values at 7 and 10 dpi (p = 0.0370 and 0.0159,
respectively) compared to the PBS-treated mice (cf. the asterisks
in Figure 3B). In contrast, the prophylactic application of IFN-α
did not change the course of the viremia. By analyzing the area
under the curves for each IFN we confirmed that a prophylaxis
with IFN-λ (Figure 3C) or a treatment after infection with IFN-
α (Figure 3D) significantly reduced the viremia compared to the
infected, untreated mice.
Combined Use of IFN-α and -λ
The combined use of both IFNswas then evaluated by duplicating
the number of applications, pre- (at−2 and−1 dpi) and/or post-
infection (at +1 and +2 dpi). Serum samples were collected at
different times from 0 to 30 dpi.
Individual samples were pooled and tested by NS3-In-Cell
ELISA (Figure 4). Infected, untreated mice (Group 7) developed
a viremia that peaked at 7 dpi and continued within similar
levels up to 30 dpi. All the IFN-treated mice evidenced a reduced
viremia for up to 7 dpi with similar titers to those found in the
naïve animals (Group 8). Four groups (1, 2, 3, and 5) maintained
those low viral titers for up to 10 dpi, while the other two groups
(4 and 6) manifested only a modest increase in virus titers. From
10 to 30 dpi, the viremia increased in almost all the groups
to reach similar levels to those observed in infected-untreated
animals (Group 7). At 30 dpi, only groups 2 and 5—and to
some extent Group 4—exhibited titers lower than those of the
untreated animals.
Individual serum samples were then analyzed by the In-Cell-
ELISA assay at 0, 4, 7, and 10 dpi. As described above, all
Frontiers in Veterinary Science | www.frontiersin.org 4 February 2020 | Volume 7 | Article 45
Quintana et al. Anti-BVDV Activity of IFNs in-vivo
FIGURE 1 | Mouse-BVDV–infection model. BALB/c mice were infected with two ncp BVDV genotype-2 strains, 98-124 and NY-93. In the figure, body weight (A);
viremia (B); and the levels of the cytokines IFN-γ (C) and TNF-α (D) in pg/ml are plotted as functions of the time in days post-infection (DPI). Key to the point and bar
textures: black, primary antibody against the NY-93 BVDV strain; gray, primary antibody against the 98-124 BVDV strain; white, mock-infected mice. The asterisks (*)
denote values significantly higher than those measured in the mock-infected mice (p < 0.05).
FIGURE 2 | Kinetics of viral replication, as measured in the BVDV levels of
blood samples of mice infected with the BVDV 98-124 strain by NS3-In-cell
ELISA. Samples were taken at different time points from 0 to 56 days
post-infection. Values are expressed as the mean NS3 titers ± SD of
triplicates.
the groups had NS3 levels significantly lower than the infected,
untreated mice (p < 0.05; Figure 5A). Table 1 lists the maximum
and minimum mean and the median values plus the standard
deviations, standard errors, and coefficients of variation for the
OD450 measured at 4 and 7 dpi. The coefficients of variation
were low (ranging from 1 to 20%), indicating that all the animals
within each group contained quite similar virus levels. In order
to define which treatment was the most effective in reducing
viremia, the area under each individual curve between 0 and
10 dpi was computed (Figure 5B). All the IFN-treated mice
evidenced significant differences in mean area under the curve
(AUC) values from that of the infected, untreated mice (p <
0.05), though groups 1, 2, and 5 were associated with the lowest
AUC values.
Viremia levels for all the IFN-treatments were compared with
the naïve group by means of the one-way ANOVA. All the pre-
and/or post-infection protocols tested resulted in significantly
lower OD450 values than those of the infected, untreated mice
of Group 7 at all three times dpi. Moreover, the values obtained
with the animals from Group 2, treated with IFN-λ at both
pre- and post-infection, did not yield significant differences from
those of the naïve mice at 4 dpi (p > 0.05, Figure 5C); whereas
on this same day the other IFN-schedules yielded higher NS3-
values than those of the naïve animals, with no differences being
found upon the use of those different protocols. None of the
values for the treated groups, however, were comparable to those
of the naïve animals at 7 and 10 dpi. The mice from group 5
exhibited lower NS3-OD450 values than did all the other INF-
treated animals at 7 dpi whereas by 10 dpi the titers of all the
groups were similar.
Systemic TNF-α and IL-10 levels were quantified in serum
samples at 2 dpi. Infected, untreated mice (Group 7) responded
to BVDV infection by secreting high levels of TNF-α (Figure 6A).
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FIGURE 3 | Effect of IFN prophylaxis or treatment in viremia. In the figures, the kinetics of viral replication, are expressed as mean OD450 ± SD of triplicate values.
Mice were inoculated with either IFN-λ (A) or IFN-α (B) before (PRE, white circles) or after (POST, gray circles) infection, or infected but left untreated (NONE, black
circles). The figures of (C) (IFN-λ) and (D) (IFN-α) are plots of the areas under the respective curves from (A,B) (mean ± SD) for the three inoculation protocols (PRE,
POST, and NONE). The corresponding values for the noninfected mice (mock-infected groups) were below the detection levels of the assay and are thus not included
in the figures. The asterisks (*) in (A,B) denote values significantly lower than those measured in the NONE group (p < 0.05). The dotted horizontal line in figures (A,B)
depict the cut-off value. DPI, days post-infection.
Similar levels of this cytokine were measured in mice that
received only one dose of IFNs, either IFN-λ as prophylaxis
(Group 6) or IFN-α post-infection (Group 3). TNF-α levels
in groups 1 and 4 (both received only IFN-α) were lower
than those observed in Group 7, but the differences were not
statistically significant (p = 0.14 and p = 0.09 for groups 1 and
4, respectively). A significant reduction in the systemic TNF-α
levels (p <0.05) was found in animals that received either IFN-
λ pre- and post-infection (Group 2), or IFN-λ pre- and IFN-
α post-infection (Group 5). By contrast, systemic IL-10 levels
did not differ statistically between all the experimental groups
(Figure 6B) although within the seven groups Group 5 displayed
the lowest level for that cytokine.
DISCUSSION
Antiviral agents can be valuable tools to control BVDV in the
field. An analysis of the activity of those agents against this virus is
critical not only for the cattle industry but also for human health,
FIGURE 4 | Effect of combined treatment in viremia. In the figure, the kinetics
of viral replication in pools of serum, expressed as NS3 titers, is plotted as a
function of the days post-infection (DPI). The arrow marks the time of infection.
The key to the experimental groups to the right of the figure, summarizes the
IFN-pre- and/or –post-infection protocol for each of the experimental groups
(G1–G8).
as BVDV has been extensively studied as a model for Hepatitis-
C virus (HCV). Because type-I and -III IFNs are produced in
response to BVDV infection (38, 39), attempts have beenmade to
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FIGURE 5 | Effect of combined treatment in viremia. (A) Viral replication was measured as the mean OD450 levels ± the SD reflecting the NS3 titer, for each of the
experimental groups G1–G7. (B) The mean value ± the SD for the area under the curve (AUC) resulting from the bar heights in (A) from days 1 through 10 is plotted
for each of the experimental groups G1–G7. (C) Viral replication was measured as in (A) for each individual animal in the groups G1–G7 plus Group G8 (the naïve
mice) at Day 4 (left figure), Day 7 (middle figure), and Day 10 (right figure) post-infection. In (B,C), different letters above the bars mark significant differences between
groups (p < 0.05).
treat PI animals with human IFN-α (23, 40); but no information
has been reported on the efficacy of that cytokine in controlling
acute BVDV infections in-vivo. Our study provides the first
evidence of the anti-BVDV activity of both IFN-α and IFN-λ
in-vivo. The present work is also the first time a murine model
has been used to study the efficacy of an antiviral compound
against BVDV.
The BVDV–BALB/c-mouse model was developed on the
basis of procedures described by Seong et al., involving the IP-
inoculation route, which resulted in more consistent viremia
levels than intranasal inoculation (26). Our results indicate that
mice can be infected by two type-2 BVDV field ncp strains of
different virulence. The difference in virulence between the two
strains was evidenced by an earlier onset of viremia in the mice
infected with the NY-93 strain than in those bearing the 98-
124 strain, and by the induction of a peak of systemic TNF-α
in all the animals infected with 98-124. None of the infected
mice developed clinical disease, coincident with previous reports
(26, 41); with the infection being verified by only the presence of
viremia, both by virus titration and RT-PCR.
We provided here two key contributions to the BVDV-
BALB/c model-namely, (1) the use of the NS3-In-Cell ELISA
to measure viremia by revealing virus infectivity directly on
the MDBK infected cells using an antibody against NS3 and
(2) the long-term follow-up of viremia. The NS3-In-Cell ELISA
recently developed by our laboratory (25) can measure viral titers
with a minimum amount (15 µl) of serum sample, enabling the
daily bleeding of animals in accordance with standard animal-
welfare regulations. Moreover, NS3 is a conserved non-structural
protein used as a marker of viral replication for any BVDV strain,
regardless their genotype or biotype. Following up viremia for
almost 2 months after infection allowed us to confirm that the
mice became chronically infected with BVDV. Another flavivirus,
the Norway-rat hepacivirus (genus Hepacivirus), persisted in
BALB/c mice for 6 weeks post-infection (42), whereas BVDV
lasted for at least 8 weeks. Moreover, that the virus could
be isolated only from the blood was interesting. Unpublished
data from our laboratory analyzing the infection of murine
splenocytes and cultured bone marrow-derived dendritic cells
(DCs) have suggested that the DCs may be responsible for
sustaining the infection in these animals. In fact, bovine DCs are
not killed by BVDV infection (29). A role of the DCs in BVDV
infection inmice—or even simply the extent of the action of those
cells in persistent infection and the lack of IFN synthesis—needs
to be confirmed by experiments aimed at this specific purpose.
The role of both Erns, which degrades double-stranded RNA,
and the capacity of N(pro) in promoting the degradation of the
murine transcription factor IRF-3 which shares 68% of homology
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4 dpi n 5 5 5 5 5 5 5 5
Minimum 0.3420 0.3000 0.3410 0.3670 0.3710 0.3650 0.7670 0.2250
Maximum 0.3670 0.3240 0.5010 0.4150 0.3870 0.3750 0.7920 0.2500
Median 0.3485 0.3165 0.3500 0.3910 0.3820 0.3710 0.7780 0.2480
Media 0.3515 0.3143 0.3855 0.3914 0.3802 0.3708 0.7790 0.2528
SD 0.0116 0.0114 0.0771 0.0175 0.0069 0.0040 0.0089 0.0271
SE 0.0058 0.0057 0.0385 0.0078 0.0031 0.0018 0.0040 0.0135
CV 3.32% 3.64% 20.01% 4.47% 1.84% 1.09% 1.15% 13.44%
7 dpi n 5 5 5 5 5 5 5 5
Minimum 0.4620 0.4600 0.6050 0.5640 0.4120 0.5390 0.8870 0.2250
Maximum 0.4950 0.5930 0.6230 0.5860 0.4870 0.5980 0.9130 0.2500
Median 0.4780 0.5255 0.6120 0.5780 0.4395 0.5545 0.9010 0.2375
Media 0.4806 0.5260 0.6130 0.5776 0.4445 0.5615 0.9002 0.2375
SD 0.0133 0.0597 0.0085 0.0087 0.0325 0.0259 0.0098 0.0123
SE 0.0059 0.0298 0.0042 0.0039 0.0163 0.0129 0.0044 0.0062
CV 2.77% 11.36% 1.38% 1.50% 7.32% 4.62% 1.10% 5.20%
SD, standard deviation; SE, standard error; CV, coefficient of variation.
with the Bos Taurus orthologous, should be also explored as
they have been associated with viral-induced immunotolerance
in cattle (43).
We have recently reported the in-vitro antiviral activity of
recombinant IFN-α and -λwith several BVDV strains of different
biotype and genotype, including field strains (25). Human IFN-α
has also prove to be effective against cp and ncp BVDVs strains
(44). Mouse IFN-α is able to reduce more than 60% BVDV
infection of mice splenocytes (unpublished data from our lab).
Recombinant mouse IFNs have exhibited potent antiviral activity
in infection models with numerous viruses such as herpes-
simplex virus-2, equine herpes virus, and influenza, among others
(16, 31). The type-I and type-III interferons have been widely
used for the treatment of HCV, another pestivirus, and preclinical
evaluations have always been performed in humanized mouse
models (45, 46). In the present experiments, both these IFN
types reduced BVDV infectivity in mice, but did not completely
block viral replication. Within the context of our experimental
design, we cannot rule out if higher doses would have resulted in
a stronger antiviral activity, though we did use a concentration
that had already been applied successfully in other similar studies
with BALB/c mice (31–34). In a study by Klinkhammer et al.
(47), 3 µg of IFN-λ had been used to prevent aerosol infection
with influenza virus along with viral transmission. In that work, a
single dose of IFN-λwas applied at 18 h pre-infection, in a design
similar to the one we used in the first experiment.
IFN-α and IFN-λ had different efficacies when applied either
before or after infection, with just a single dose of IFN-λ being
more efficient in preventing BVDV infection and with IFN-α
providing a better treatment against this virus. IFN-λ receptors
are predominantly expressed in epithelial cells; thus, if BVDV
uses epithelial cells as a primary replication site, we might
conceivably expect an enhanced activity of IFN-λ at that stage.
IFN-α receptors are present in a large number of cells (11)
and tissues, including blood cells—probably there to prevent
viral spread from the initial replication site. For an airborne
transmitted virus as VDVB, as the use of IFN-λ may be useful
protect the animals at the virus entry site.
Upon analyzing the antiviral capability of IFN-α and -λ
on HCV, Marcello et al. (48) proposed that the combined
use of both IFNs could achieve better results since the
kinetics of the genes inducible by those two IFNs complement
each other, which combined activity would generate a better
antiviral response. Our study is the first one reporting the
antiviral activity of the combined use of IFN-α and -λ in-
vivo. The use of both IFNs, independently of the scheme,
significantly reduced viremia in the infected mice, revealing
that increasing the number of applications was more effective
than using just one, as expected. Interestingly, IFN-λ applied
both before and after infection was an effective treatment,
enabling the use of just one cytokine. This result should be
considered when designing a trial viral-challenge experiment
in cattle.
Our results indicate that infection with 98-124 strain induce
a peak of systemic TNF-α at 2 dpi in mice and we observed
also that TNF-α was downregulated in most of the IFN-treated
group, with significantly lower levels in groups 2 and 5, those
being also the ones with the lowest viremia levels. Therefore, we
associated the reduced serum concentration of this cytokine with
a lower viral replication. We cannot, however, rule out a possible
role of these cytokines in modulating the immune response (49),
since IFN-α is known to negatively regulate the expression of the
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FIGURE 6 | Systemic cytokine levels. In the figures, the mean concentrations
± SD of IFN-α (A) or IL-10 (B) in pg/ml of individual serum samples at 2 dpi
are plotted for each experimental group. The asterisks (*) denote significant
differences compared to the corresponding levels measured in the infected,
untreated animals (Group 7) at a p < 0.05.
proinflammatory cytokines IL-1ß and TNF-α in mice (16), and
also suppress IFN-γ production.
In veterinary medicine, because the use of antiviral agents
against BVDV has always been focused on treating PI animals,
those preparations have not been explored for the possible
prevention or treatment of acute infections. We, however,
envision the eventual application of IFN-λ in the case of an
acute outbreak to reduce viral circulation within the interval
between the time of vaccination and onset of protection,
potentially closing that window of vulnerability. In the instance
where the virus has circulated during the pregnancy period,
the pregnant animals can be treated with IFN-λ to prevent
transmission, as innate mechanisms of immunity are active
even during the fetal period (50). The possibility of expressing
bovine IFNs as recombinant proteins (25, 51) furthermore
opens up a new scenario for preventing and treating bovine
viral infections in the field. Studies in cattle are needed to
confirm the activity of IFN-λ in the natural host and to evaluate
the time-span of its biological activity, in order to define
how long an IFN application can protect against infection in
the field.
In conclusion, our results have demonstrated that the BVDV-
BALB/c–mouse model constitutes a useful tool to investigate
BVDV infection in-vivo, and have underscored the efficacy of
IFN-λ in reducing BVDV infection in-vivo, thus establishing
a promising clinical support for the possibility of testing this
interferon in bovines.
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